Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 2,048 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Malignant Childhood Neoplasm Clear all
Completed Phase 1 Interventional Results available

Safety Study to Evaluate FluMist in Immunocompromised Children

NCT00112112
View directory record Official record
Conditions
Cancer
Interventions
FluMist, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
5 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Rochester, New York • Stony Brook, New York • Memphis, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Nov 6, 2026, 1:45 PM EST
Terminated Not applicable Interventional

7T MRI Scan for the Early Detection of Melanoma Brain Metastases

NCT04941430
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions
Magnetic Resonance Imaging using 7 Tesla MRI
Diagnostic Test
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Nov 6, 2026, 1:45 PM EST
Completed No phase listed Observational

The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases

NCT01423734
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor, Secondary Malignant Neoplasm of Liver
Interventions
magnetic resonance imaging (MRI)
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Nov 6, 2026, 1:45 PM EST
Completed Phase 1Phase 2 Interventional Results available

Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma

NCT00715793
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Decitabine, Temozolomide, biopsy
Drug · Procedure
Lead sponsor
Hussein Tawbi
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Nov 6, 2026, 1:45 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Evaluation of a Healthy Lifestyle Intervention for Adolescent and Young Adult Survivors of Pediatric Cancer

NCT04839952
View directory record Official record
Conditions
Pediatric Cancer
Interventions
Healthy Lifestyles, Education-Only Control
Behavioral
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
15 Years to 25 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Nov 6, 2026, 1:45 PM EST
Active, not recruiting Phase 2 Interventional Results available

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

NCT05490771
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 6, 2026, 1:45 PM EST
Recruiting Not applicable Interventional

Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

NCT03184038
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
Interventions
Cognitive Assessment, Stereotactic Radiosurgery, Stereotactic Body Radiation Therapy, Quality-of-Life Assessment
Procedure · Radiation · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Sewell, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 6, 2026, 1:45 PM EST
Completed Phase 1 Interventional Results available

Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

NCT02808650
View directory record Official record
Conditions
Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm
Interventions
Laboratory Biomarker Analysis, Pharmacokinetic (PK) study, Prexasertib
Other · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Nov 6, 2026, 1:45 PM EST
Active, not recruiting Phase 2 Interventional Results available

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

NCT04439110
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Trastuzumab Emtansine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 6, 2026, 1:45 PM EST
Completed Not applicable Interventional

Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell Cancer

NCT03575949
View directory record Official record
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Malignant Neoplasm in the Spine
Interventions
Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Nov 6, 2026, 1:45 PM EST
Completed Phase 2 Interventional

Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer

NCT00003408
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions
aldesleukin, recombinant interferon alfa, sargramostim
Biological
Lead sponsor
Cancer Treatment Centers of America
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Nov 6, 2026, 1:45 PM EST
Terminated Not applicable Interventional

Brief Mindful Meditation Practice in Improving Quality of Life in Patients With Cancer Undergoing Radiation Therapy

NCT02170350
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Meditation therapy, Quality-of-life assessment, Questionnaire administration
Procedure · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Nov 6, 2026, 1:45 PM EST
Active, not recruiting No phase listed Observational

An Evaluation of Concordance of Smartwatch ECG and One Clinical ECG and Comparison of The Two ECGS in Terms of Predictive Risks

NCT05617391
View directory record Official record
Conditions
Childhood Cancer, Cardiomyopathy, Primary
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
22 Years and older
Enrollment
1,303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Nov 6, 2026, 1:45 PM EST
Withdrawn Not applicable Interventional

Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma

NCT02540135
View directory record Official record
Conditions
High Grade Malignant Neoplasm, Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
fluorescein, intraoperative MRI
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Nov 6, 2026, 1:45 PM EST
Completed Not applicable Interventional Results available

Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer

NCT02823652
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Locally Advanced Malignant Neoplasm
Interventions
standard genetic education, Genetic Counseling, Genetic Testing, Internet-Based Intervention, Survey Administration
Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Nov 6, 2026, 1:45 PM EST
Not listed Phase 1 Interventional

Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide

NCT00102648
View directory record Official record
Conditions
Malignant Supratentorial Neoplasm, Recurrent Glioblastoma, Recurrent Gliosarcoma
Interventions
Lonafarnib, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Nov 6, 2026, 1:45 PM EST
Not listed No phase listed Observational

Survey of Cancer Patients' Perceptions of Difficulties Encountered When Filling Opioid Prescriptions

NCT03989128
View directory record Official record
Conditions
Malignant Neoplasm, Pain
Interventions
Medical Chart Review, Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Nov 6, 2026, 1:45 PM EST
Active, not recruiting Phase 2 Interventional Results available

Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors

NCT03035409
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, C-Reactive Protein Measurement, Cancer Fatigue, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Weight Loss
Interventions
Anamorelin Hydrochloride, Exercise Intervention, Laboratory Biomarker Analysis, Nutritional Assessment, Quality-of-Life Assessment, Questionnaire Administration
Drug · Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Nov 6, 2026, 1:45 PM EST
Not yet recruiting No phase listed Observational

Tumor-Lymph Node Mapping

NCT07054944
View directory record Official record
Conditions
Pediatric Solid Tumors, Rhabdomyosarcoma, Sarcoma, Germ Cell Tumor
Interventions
ICG (Indocyanine Green)
Diagnostic Test
Lead sponsor
University of Rochester
Other
Eligibility
1 Month to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 6, 2026, 1:45 PM EST
Completed No phase listed Observational

Questionnaires in Assessing Attitudes About Legalization of Marijuana Use in Participants With Cancer

NCT03360799
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Gilbert, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Nov 6, 2026, 1:45 PM EST
Active, not recruiting Phase 2 Interventional Results available

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

NCT03212274
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
51
States / cities
Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 6, 2026, 1:45 PM EST
Active, not recruiting No phase listed Observational

Financial Distress in Advanced Cancer Patients

NCT04053517
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
Interventions
Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 6, 2026, 1:45 PM EST
Completed Not applicable Interventional

Talking Pictures Social Media Intervention in Reducing Depressive Symptoms and Improving Spiritual Well-Being and Quality of Life in Adolescent and Young Adult Cancer Patients

NCT03679585
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
15 Years to 34 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Nov 6, 2026, 1:45 PM EST
Completed No phase listed Observational

DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings

NCT01434355
View directory record Official record
Conditions
Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Ovarian Choriocarcinoma, Ovarian Embryonal Carcinoma, Ovarian Mixed Germ Cell Tumor, Ovarian Teratoma, Ovarian Yolk Sac Tumor, Testicular Choriocarcinoma, Testicular Embryonal Carcinoma, Testicular Seminoma, Testicular Teratoma, Testicular Yolk Sac Tumor
Interventions
Laboratory Biomarker Analysis, Questionnaire Administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 19 Years
Enrollment
932 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Nov 6, 2026, 1:45 PM EST